



A Randomized, Multicenter, Double-Masked, Vehicle-Controlled Phase 2/3 Study to Evaluate the Safety and Efficacy of NEXAGON? (Lufepirsen Ophthalmic Gel) in Subjects with Persistent Corneal Epithelial Defects (NEXPEDE-1)

Status: Recruiting

# Eligibility Criteria

Sex: Male or Female Age Group: Not specified This study is NOT accepting healthy

#### **Inclusion Criteria:**

- at least 2 years old - diagnosis of Persistent Corneal Epithelial Defect (PCED) for at least 2 weeks that hasn't responded to one or more conventional non-surgical treatments

#### **Exclusion Criteria:**

- active eye infection that requires treatment - additional eye conditions that exclude study participation (study staff will review)

## Conditions & Interventions

Interventions:

Drug: Vehicle, Drug: Iufepirsen

Conditions: Vision & Eyes Keywords:

Cornea, Persistent Corneal Epithelial Defect, Vision Loss

### More Information

Description: The clear layer at the front of the eye that covers the pupil and iris (colored part of the eye) is called the "cornea". When the cornea is damaged, it normally heals within a few days but it may take up to 2 weeks depending on the size and depth of the defect (wound). Some corneal defects heal much slower than expected. A defect in the cornea that fails to heal within the normal time of 2 weeks despite using the best available medicines and procedures, is known as Persistent Corneal Epithelial Defect (or PCED for short). The purpose of this research study is to evaluate the safety, tolerability, and effectiveness (risks and benefits) of of NEXAGON ophthalmic gel for the treatment of PCEDs.

Study Contact: Meaghyn Kramer - krame706@umn.edu

Principal Investigator: Joshua Hou

IRB

SITE00002014 Number:

Thank you for choosing StudyFinder. Please visit http://studyfinder.umn.edu to find a Study which is right for you and contact sfinder@umn.edu if you have questions or need assistance.